59.1 Osteoarthritis: Hip, Knee & Hand Management

Pathophysiology & Cellular Mechanisms of Osteoarthritis

Osteoarthritis (OA) is the most prevalent chronic articular disorder worldwide and the leading cause of chronic disability and impaired mobility in older adults. Historically mischaracterized as a passive, non-inflammatory "wear-and-tear" degradation of articular cartilage, contemporary molecular rheumatology defines OA as an active, metabolically driven, whole-organ disease of the synovial joint. The pathological process involves the coordinated degeneration of articular hyaline cartilage, extensive remodeling of subchondral bone, formation of marginal osteophytes, low-grade synovial inflammation (synovitis), thickening of the joint capsule, and degeneration of intra-articular ligaments and menisci.

1. Articular Cartilage Degradation & Chondrocyte Senescence

Normal articular hyaline cartilage is an avascular, aneural, and alymphatic tissue composed of extracellular matrix (ECM)—predominantly type II collagen fibrils and aggregated proteoglycans (aggrecan)—maintained by a specialized, sparse population of chondrocytes. In healthy cartilage, chondrocytes balance low-level matrix synthesis with matrix degradation.

• Phenotypic Shift: In OA, mechanical shear stress, advanced glycation end-products (AGEs), and local biochemical cues trigger a phenotypic transition of chondrocytes from a quiescent state to an abnormal "hypertrophic" or catabolic phenotype.
• Catabolic Proteases: Hypertrophic chondrocytes markedly upregulate matrix-degrading metalloproteinases, specifically Matrix Metalloproteinase-13 (MMP-13) (which selectively degrades type II collagen triple helices) and aggrecanases belonging to the ADAMTS family (ADAMTS-4 and ADAMTS-5). Degradation of aggrecan causes loss of fixed negative charges (chondroitin sulfate and keratan sulfate glycosaminoglycan side chains), leading to loss of cartilage water-binding capacity and compressive stiffness.
• Fibrillation & Erosion: As the collagen meshwork fractures, cartilage undergoes swelling, surface fibrillation, vertical clefting, and progressive full-thickness erosion down to bare subchondral bone.

2. Subchondral Bone Remodeling: Sclerosis, Osteophytes & Geodes

The osteochondral junction experiences profound pathological remodeling during OA progression:

• Subchondral Bone Sclerosis (Eburnation): Increased osteoclast-mediated bone resorption initially occurs, followed by aberrant osteoblast activation and deposition of hypomineralized, dense woven bone (eburnation). This thickened, sclerotic subchondral bone is stiffer than normal trabecular bone, reducing its shock-absorbing capacity and transferring excessive peak compressive loads back onto the surviving articular cartilage, accelerating cartilage loss.
• Marginal Osteophytes: At joint margins where cartilage meets periosteum and synovium, vascular invasion and elevated concentrations of growth factors—particularly Transforming Growth Factor-beta (TGF-β) and Bone Morphogenetic Proteins (BMP-2, BMP-4)—induce mesenchymal stem cell chondrogenesis followed by endochondral ossification. The resulting bony outgrowths (osteophytes) represent an adaptive, biomechanical attempt to broaden joint surface area and redistribute load, but often restrict joint mobility and impinge on adjacent soft tissues.
• Subchondral Cysts (Geodes): Microfractures in the weakened, sclerotic subchondral plate allow pressurized intra-articular synovial fluid to be driven into the subchondral trabeculae during weight-bearing ("hydraulic pumping mechanism"). Alternatively, localized osteonecrosis and focal osteoclastic resorption create cystic cavities filled with fibrous tissue or gelatinous myxoid fluid.

3. Low-Grade Synovial Inflammation

Although OA lacks the intense, pannus-forming neutrophilic or lymphoplasmacytic infiltration seen in rheumatoid arthritis, low-grade chronic synovitis is present in the vast majority of symptomatic patients:

• Breakdown fragments of cartilage matrix (fibronectin fragments, degraded type II collagen, low-molecular-weight hyaluronan) act as Damage-Associated Molecular Patterns (DAMPs).
• These DAMPs bind to pattern recognition receptors, particularly Toll-Like Receptors 2 and 4 (TLR-2, TLR-4), on synovial macrophages and fibroblast-like synoviocytes.
• Receptor activation triggers NF-κB signaling, inducing the secretion of pro-inflammatory cytokines (Interleukin-1β [IL-1β], Tumor Necrosis Factor-alpha [TNF-α], and Interleukin-6 [IL-6]), nitric oxide, and prostaglandin E2 ($\text{PGE}_2$). These mediators diffuse back across the joint space to further stimulate chondrocyte apoptosis and catabolism in a self-amplifying feed-forward loop.

---

Epidemiological & Biomechanical Risk Factors

                  SYSTEMIC AND BIOMECHANICAL RISK FACTORS FOR OSTEOARTHRITIS

   Factor Category         Specific Etiologic Factor        Pathophysiological Mechanism
   ═════════════════════════════════════════════════════════════════════════════════════════════════════════════
   Systemic / Constitutional • Advanced Age (>50-60 years)   Accumulation of AGEs, chondrocyte senescence, loss of ECM
                             • Female Sex                   Estrogen withdrawal post-menopause; altered joint kinematics
                             • Genetics / Heredity          Heritability ~40-60%; polygenic traits affecting COL2A1, GDF5
   ─────────────────────────────────────────────────────────────────────────────────────────────────────────
   Metabolic / Endocrine     • Obesity (Adipokines)         Adipose secretion of LEPTIN, RESISTIN, and TNF-α inducing
                                                            cartilage catabolism; metabolic syndrome synergy
   ─────────────────────────────────────────────────────────────────────────────────────────────────────────
   Biomechanical / Mechanical • Excess Weight (Mechanical)   Every 1 lb of weight increases compressive load by 4 lbs
                                                            across the tibiofemoral knee joint per step
                             • Prior Joint Trauma           Post-traumatic OA (ACL rupture, meniscal tear, ankle fracture)
                             • Occupational Overuse         Repetitive squatting, heavy lifting (>25 kg), kneeling
                             • Joint Malalignment           Genu varum (medial load) vs Genu valgum (lateral load);
                                                            cam/pincer femoroacetabular impingement (FAI)
   ═════════════════════════════════════════════════════════════════════════════════════════════════════════════

[!NOTE] THE BIOMECHANICS OF WEIGHT LOSS IN OSTEOARTHRITIS During standard ground-level walking, ground reaction forces and quadriceps muscle contractions multiply the compressive force across the knee joint to 3 to 5 times total body weight. Consequently, a weight loss of just 10 pounds (4.5 kg) relieves an astonishing 30 to 50 pounds of joint compressive load with every single step taken. Furthermore, visceral adipose tissue actively synthesizes pro-inflammatory adipokines (leptin, resistin) that cross the synovial barrier and stimulate chondrocyte MMP-13 production. Weight reduction therefore confers a powerful dual benefit: profound mechanical unloading combined with systemic anti-inflammatory hormonal suppression.

---

Clinical Manifestations & Physical Examination

The onset of osteoarthritis is typically insidious, evolving over months to years. Clinicians must recognize cardinal symptoms, physical examination findings, and key discriminators that differentiate OA from inflammatory and systemic arthritides.

1. Cardinal Symptoms

• Mechanical Joint Pain: The hallmark of OA is deep, dull, aching pain localized to the affected joint that is characteristically worsened by weight-bearing, physical activity, and joint use, and relieved by rest. In early stages, pain is intermittent; in advanced end-stage disease, pain becomes persistent, occurring at rest and waking the patient at night.
• Brief Morning Stiffness: Joint stiffness upon awakening characteristically lasts less than 30 minutes (typically 5 to 15 minutes). This represents a vital clinical discriminator: morning stiffness persisting for >60 minutes strongly points toward an inflammatory systemic arthropathy (such as Rheumatoid Arthritis, Psoriatic Arthritis, or Polymyalgia Rheumatica).
• The "Gel Phenomenon": Transient joint stiffness that develops following periods of daytime rest or immobility (e.g., stiffness upon standing after sitting in a car or chair for an hour). The gel phenomenon in OA resolves rapidly within a few minutes of gentle joint movement.

2. Physical Examination Findings

• Bony Crepitus: A palpable (and sometimes audible) rough, grinding, crunching sensation felt throughout passive or active range of motion, caused by the friction of denuded, roughened cartilaginous surfaces and eburnated bone rubbing together.
• Joint Line Tenderness: Well-localized tenderness elicited along the anatomical margins of the joint (e.g., medial or lateral tibiofemoral joint line).
• Bony Enlargement vs. Synovial Proliferation: Palpable hard, unyielding, non-tender bony enlargements caused by marginal osteophytes. This contrasts sharply with the soft, spongy, "boggy", warm synovial hypertrophy characteristic of rheumatoid arthritis.
• Cool, Non-Inflammatory Effusions: Joint effusions, when present, are typically mild to moderate in volume and "cool" (lacking significant erythema or warmth). Arthrocentesis reveals clear, straw-colored fluid with high viscosity, a white blood cell count <2,000/mcL, and <25% polymorphonuclear neutrophils (Class I / non-inflammatory synovial fluid).
• Restricted Range of Motion & Muscle Atrophy: Progressive loss of joint excursion due to osteophytic impingement, capsular fibrosis, and joint surface incongruity. Periarticular muscle disuse atrophy is prominent (e.g., marked quadriceps wasting in advanced knee OA).

                  CLINICAL DIFFERENTIATION: OSTEOARTHRITIS VS. RHEUMATOID ARTHRITIS

   Feature                 Osteoarthritis (OA)                     Rheumatoid Arthritis (RA)
   ═════════════════════════════════════════════════════════════════════════════════════════════════════════════
   Pathophysiology         Biomechanically driven cartilage loss,  Autoimmune chronic inflammatory synovitis with
                           subchondral sclerosis, and osteophytes  pannus formation and bone erosions

   Pattern of Involvement  Asymmetric, oligoarticular or monoarticular; Symmetrical, polyarticular (>4 joints);
                           weight-bearing joints (knees, hips)     small joints of hands, wrists, and feet

   Morning Stiffness       Brief, < 30 minutes; transient gel      Prolonged, > 60 minutes (often lasting
                           phenomenon after inactivity             several hours or all morning)

   Pain Characteristics    Worsened by activity / weight-bearing;  Improves with activity; worsened by rest
                           relieved by rest                        and prolonged immobility

   Hand Joint Predilection DIP, PIP, and 1st CMC (thumb base);     MCP, PIP, and Wrist joints;
                           STRICTLY SPARES MCP JOINTS              STRICTLY SPARES DIP JOINTS

   Palpation / Effusions   Hard, bony enlargement (Heberden/       Soft, warm, "boggy" synovial hypertrophy;
                           Bouchard nodes); cool effusions         hot, erythematous inflammatory effusions

   Systemic Symptoms       Absent (no fever, fatigue, weight loss) Prominent (malaise, fatigue, rheumatoid nodules)

   Laboratory Markers      Normal ESR and CRP; negative RF and     Elevated ESR and CRP; positive RF and
                           anti-CCP; WBC < 2,000 in synovial fluid anti-CCP; WBC 2,000 - 50,000 in synovial fluid

   Radiographic Hallmarks  Asymmetric joint space narrowing,       Symmetric joint space narrowing, periarticular
                           subchondral sclerosis, osteophytes,     osteopenia, marginal bone erosions WITHOUT
                           subchondral cysts (geodes)              osteophyte formation
   ═════════════════════════════════════════════════════════════════════════════════════════════════════════════

---

Anatomical Subtypes & Clinical Phenotypes

1. Hand Osteoarthritis

Hand OA exhibits a striking predilection for specific digit joints, with characteristic physical manifestations:

• Heberden Nodes: Hard, palpable, bony enlargements located on the dorsolateral aspects of the Distal Interphalangeal (DIP) joints, representing marginal osteophytes.
• Bouchard Nodes: Bony prominences located at the Proximal Interphalangeal (PIP) joints.
• 1st Carpometacarpal (CMC / Trapeziometacarpal) Joint OA: Involvement of the base of the thumb causes localized tenderness, functional weakness in grip and pinch strength, and a prominent "squared" appearance of the hand base. The Grind Test (axial compression and circumduction/rotation of the thumb metacarpal against the trapezium) reproduces sharp localized pain and crepitation.
• CRITICAL EXAM PEARL: Sparing of the Metacarpophalangeal (MCP) Joints: Osteoarthritis spares the MCP joints and wrist joints. Involvement of MCP joints or wrists with swelling, tenderness, and warmth is the classic presentation of Rheumatoid Arthritis. (Exception: Isolated 2nd and 3rd MCP joint narrowing with "hook-like" osteophytes is pathognomonic for Hemochromatosis / Calcium Pyrophosphate Deposition disease).
• Erosive Hand OA: An aggressive, highly inflammatory subset of hand OA occurring predominantly in postmenopausal females. Presents with abrupt, painful, erythematous flares of DIP and PIP joints. Radiographs reveal central subchondral bone erosions paired with marginal bone proliferation, producing the classic "gull-wing" or "sawtooth" contour.

2. Knee Osteoarthritis

The knee joint comprises three distinct functional compartments: the medial tibiofemoral, lateral tibiofemoral, and patellofemoral compartments:

• Medial Compartment: Most commonly affected by OA due to the physiological adduction moment during gait, which concentrates 60% to 70% of ground reaction forces across the medial plateau. Progressive medial cartilage loss produces an asymmetric narrowing that tilts the lower extremity into Genu Varum (bow-legged deformity).
• Lateral Compartment: Less frequently isolated; progressive lateral joint space loss results in Genu Valgum (knock-knee deformity).
• Patellofemoral Compartment: Characterized by anterior knee pain that is sharply exacerbated by stair climbing, descending stairs, squatting, or prolonged sitting with flexed knees ("theater sign"). Physical exam reveals crepitus beneath the patella and a positive patellar grind (Clarke) test.

3. Hip Osteoarthritis

• Pain Localization: The true intra-articular hip joint is innervated primarily by the femoral, obturator, and sciatic nerves. Consequently, hip OA pain classically manifests as deep groin pain radiating into the anterior thigh, buttock, or down to the ipsilateral knee.
• The Knee Pain Distractor: Many patients with advanced hip OA present complaining primarily of medial knee pain (referred via the anterior branch of the obturator nerve). Primary care physicians must examine the hip in any older adult presenting with unexplained knee pain.
• Physical Exam Pearls: The earliest physical finding of hip OA is limitation and pain during internal rotation with the hip flexed to 90 degrees (normal internal rotation is approximately 35° to 45°; restriction to <15-20° strongly suggests OA). The FABER (Patrick) test (Flexion, ABduction, External Rotation) reproduces deep groin pain. Advanced disease produces an antalgic Trendelenburg gait (the patient shifts the torso over the affected hip during the stance phase to decrease abductor muscle contraction force and reduce joint compressive load).
• Trochanteric vs. Intra-articular Pain: Pain localized strictly over the lateral aspect of the hip (greater trochanteric prominence) that is aggravated by direct pressure (lying on that side in bed) is Greater Trochanteric Pain Syndrome (gluteal tendinopathy / trochanteric bursitis), NOT intra-articular hip osteoarthritis.

---

Radiographic Hallmarks & Kellgren-Lawrence Grading

When osteoarthritis is clinically suspected, plain radiography represents the initial diagnostic imaging modality of choice. Routine magnetic resonance imaging (MRI) is not indicated for uncomplicated OA, as MRI is excessively sensitive, reveals incidental meniscal tears that do not require surgical intervention, and does not alter non-surgical management.

[!IMPORTANT] MANDATORY WEIGHT-BEARING RADIOGRAPHIC PROTOCOL Radiographs of the lower extremity joints MUST be performed in the standing, weight-bearing position. Non-weight-bearing (supine) radiographs fail to demonstrate physiological joint space narrowing and will significantly underestimate disease severity. Standard knee series must include: 1) Standing AP view, 2) Standing lateral view, 3) 45-degree flexion posteroanterior (Rosenberg) view (detects early posterior joint space narrowing), and 4) Merchant or sunrise axial view (evaluates the patellofemoral joint). Hip evaluation requires a standing AP pelvis and frog-leg lateral view.

The Four Cardinal Radiographic Signs of Osteoarthritis

1. Asymmetric Joint Space Narrowing: Loss of articular hyaline cartilage thickness localized to the primary load-bearing compartment (e.g., medial compartment of the knee, superior pole of the acetabulum). This contrasts with the uniform, symmetric joint space narrowing seen across inflammatory joint diseases.
2. Subchondral Bone Sclerosis: Dense, ivory-white radiodense band of bone thickening immediately adjacent to the denuded joint line (eburnation).
3. Marginal Osteophytes: Bony projections or spurs arising at articular margins.
4. Subchondral Cysts (Geodes): Well-circumscribed, round or oval radiolucencies with sclerotic margins located in the subchondral bone.

                  THE KELLGREN-LAWRENCE (KL) RADIOGRAPHIC GRADING SYSTEM

   Grade       Classification    Radiographic Criteria                                 Clinical Correlate
   ═════════════════════════════════════════════════════════════════════════════════════════════════════════════
   Grade 0     None              No radiographic features of osteoarthritis            Normal joint
   ─────────────────────────────────────────────────────────────────────────────────────────────────────────
   Grade 1     Doubtful          Minute, doubtful osteophytic lipping;                 Minimal or asymptomatic;
                                 possible joint space narrowing                        rarely clinically diagnosed
   ────────────────────────────────────────────────────────────────────────────────════════════════════════
   Grade 2     Mild              Definite marginal osteophytes;                        Mild, intermittent symptoms;
                                 possible or unimpaired joint space narrowing          definite structural OA
   ─────────────────────────────────────────────────────────────────────────────────────────────────────────
   Grade 3     Moderate          Moderate, multiple osteophytes; definite joint space  Moderate to severe mechanical pain;
                                 narrowing; some subchondral sclerosis; possible cysts functional limitations
   ─────────────────────────────────────────────────────────────────────────────────────────────────────────
   Grade 4     Severe            Large osteophytes; marked/severe joint space          Severe, intractable pain; rest/night
                                 narrowing (bone-on-bone); severe sclerosis; deformity pain; candidate for arthroplasty
   ═════════════════════════════════════════════════════════════════════════════════════════════════════════════

Clinical-Radiographic Discordance: Radiographic severity correlates imperfectly with clinical symptoms. Approximately 30% to 40% of patients with severe KL Grade 4 radiographic changes experience minimal or manageable pain, whereas patients with mild KL Grade 1-2 changes may suffer from severe, debilitating pain. Clinical management must treat the patient's pain and functional impairment, not the X-ray alone.

---

American College of Rheumatology (ACR 2019) Treatment Guidelines

The American College of Rheumatology (ACR) and Arthritis Foundation published comprehensive, evidence-based guidelines classifying therapeutic modalities for knee, hip, and hand OA based on high-quality randomized controlled trials.

                  ACR 2019 OSTEOARTHRITIS TREATMENT RECOMMENDATIONS

   Recommendation Tier       Therapeutic Modality                   Joint Sites & Clinical Directives
   ═════════════════════════════════════════════════════════════════════════════════════════════════════════════
   STRONGLY RECOMMENDED      • Land-based physical exercise / PT     Knee, Hip, Hand (quadriceps/core strengthening)
                             • Weight loss (>= 5% to 10% reduction) Knee, Hip (reduces mechanical load & adipokines)
                             • Topical NSAIDs (Diclofenac 1% gel)   KNEE OA: FIRST-LINE PHARMACOTHERAPY
                             • Oral NSAIDs (lowest effective dose)  Knee, Hip, Hand (co-prescribe PPI if GI risk)
                             • Tai Chi                              Knee, Hip (balance, proprioception, pain relief)
                             • Walking cane / assistive devices     Knee, Hip (contralateral hand to unload joint)
                             • First CMC joint splints / orthoses   Hand OA (stabilizes trapeziometacarpal joint)
   ─────────────────────────────────────────────────────────────────────────────────────────────────────────
   CONDITIONALLY RECOMMENDED • Intra-articular Corticosteroids      Knee, Hip (short-term 4-8 week flare relief)
                             • Duloxetine (SNRI 30 - 60 mg daily)   Knee, Hip (ideal for multi-joint / centralized pain)
                             • Topical Capsaicin                    Knee OA only (depletes substance P)
                             • Chondroitin Sulfate                  HAND OA ONLY (strongly against for knee/hip)
                             • Radiofrequency ablation / genicular  Knee OA (refractory to meds, nonsurgical candidates)
                             • Balance / gait training exercises    Knee, Hip
   ─────────────────────────────────────────────────────────────────────────────────────────────────────────
   STRONGLY RECOMMENDED      • Hyaluronic Acid (HA) Injections      Knee, Hip (marginal benefit, high cost, pseudosepsis)
   AGAINST (DO NOT USE)      • Glucosamine & Chondroitin            Knee, Hip (no proven structural/clinical benefit)
                             • Opioid Analgesics (routine use)      Knee, Hip, Hand (dependence, falls, hyperalgesia)
                             • Stem Cell / PRP Injections           Knee, Hip (lack of standardization / proven efficacy)
                             • Oral Hydroxychloroquine / Biologics  Hand, Knee, Hip (ineffective for OA)
   ═════════════════════════════════════════════════════════════════════════════════════════════════════════════

1. Strongly Recommended Non-Pharmacologic Foundations

• Structured Exercise Programs: Exercise is the cornerstone of conservative therapy. Land-based physical therapy focusing on progressive quadriceps strengthening, hip abductor (gluteus medius) strengthening, and low-impact aerobic conditioning (walking, stationary cycling, aquatic therapy) significantly reduces pain and improves physical function with effect sizes comparable to oral NSAIDs. Tai Chi combines slow, controlled weight-shifting with mental focus, providing proven improvements in balance, postural stability, and pain reduction.
• Weight Loss: For overweight or obese individuals with knee or hip OA, a weight loss of >=5% of baseline body weight produces measurable reductions in joint pain and functional improvement; a loss of >=10% body weight slows articular cartilage loss on MRI and provides profound, clinically transformative relief.
• Biomechanical Assistive Devices: A single-point cane should be held in the hand contralateral to the affected lower extremity (advancing the cane simultaneously with the affected leg). This biomechanical positioning reduces abductor muscle contraction across the diseased hip or knee, unloading the joint by up to 50% to 60%. For unicompartmental medial knee OA, a valgus unloader knee brace applies a corrective lateral force during ambulation, decreasing medial compartment joint stress.

2. Pharmacotherapy: Nuances, Safety & Risk Mitigation

• Topical NSAIDs (Diclofenac 1% Gel / Patch / Solution):
  • FIRST-LINE PHARMACOTHERAPY FOR KNEE OA: The 2019 ACR guidelines strongly recommend topical NSAIDs as initial pharmacologic therapy for knee OA, ahead of oral NSAIDs.
  • Topical diclofenac delivers local anti-inflammatory drug concentrations to periarticular tissues and cartilage equivalent to oral formulations, but systemic plasma absorption is <5% to 10% of oral dosing.
  • Yields equivalent analgesic efficacy to oral NSAIDs with dramatically lower incidences of gastrointestinal ulceration, renal toxicity, and cardiovascular thrombotic events.
  • Particularly mandatory in patients aged >=65 years, those with a history of peptic ulcer disease, mild-to-moderate chronic kidney disease, hypertension, or cardiovascular disease.
• Oral NSAIDs:
  • Indicated for knee, hip, and hand OA when topical therapy is ineffective, impractical (e.g., deep hip joints cannot be reached by topical preparations), or when multiple joints are involved.
  • Prescribe at the lowest effective dose for the shortest possible duration, or use on an intermittent, PRN basis.
  • Gastrointestinal Risk Mitigation: In patients with elevated GI bleeding risk (age >=65, history of peptic ulcer disease, concomitant use of aspirin, anticoagulants, or systemic corticosteroids), co-prescribe a Proton Pump Inhibitor (PPI) (e.g., omeprazole 20 mg daily) or use a selective COX-2 inhibitor (celecoxib 100-200 mg daily). Note: Co-administration of low-dose aspirin eliminates celecoxib's GI safety advantage, necessitating a PPI.
  • Cardiovascular & Renal Monitoring: All oral NSAIDs (selective and non-selective) inhibit renal prostaglandins ($\text{PGE}_2$, $\text{PGI}_2$), causing sodium retention, blunting antihypertensive efficacy, elevating blood pressure, and increasing risks of acute kidney injury and heart failure exacerbations. Avoid in patients with severe CKD (eGFR <30 mL/min/1.73 m²) or severe heart failure.
• Acetaminophen (Paracetamol):
  • Meta-analyses demonstrate that acetaminophen has a very small, clinically negligible effect size in OA pain reduction. The ACR 2019 guidelines downgraded acetaminophen to conditionally recommended solely as an adjunctive short-term option for patients who cannot tolerate or have contraindications to NSAIDs.
  • Maximum daily dose must not exceed 3,000 mg/day (or 2,000 mg/day in older adults or those with mild liver disease) to avoid hepatotoxicity.
• Duloxetine (Cymbalta):
  • Serotonin-Norepinephrine Reuptake Inhibitor (SNRI) dosed at 30 to 60 mg orally once daily.
  • Conditionally recommended for knee, hip, and multi-joint OA, particularly when complicated by centralized pain amplification, depression, or neuropathic pain components.

3. Interventional Therapies: The Evidence

• Intra-articular Corticosteroid Injections:
  • Formulation: Triamcinolone acetonide (40 mg) or methylprednisolone acetate (40 mg) combined with 1-2 mL of local anesthetic (1% lidocaine or 0.5% bupivacaine).
  • Clinical Role: Conditionally recommended for acute inflammatory flares with effusion refractory to topical/oral therapies.
  • Duration of Efficacy: Provides rapid, significant pain relief that peaks at 1 to 2 weeks, but benefits typically wane after 4 to 8 weeks.
  • Critical Caution: Large randomized trials (e.g., McAlindon et al., JAMA 2017) demonstrated that repeated intra-articular steroid injections every 3 months over 2 years resulted in greater articular cartilage volume loss on MRI without sustained clinical improvement compared to saline. Clinical consensus mandates limiting injections to no more than 3 to 4 times per year in a given joint.
• Hyaluronic Acid (HA) Viscosupplementation: STRONGLY RECOMMENDED AGAINST:
  • Despite widespread marketing, rigorous systematic reviews and the ACR guidelines conclude that intra-articular HA provides minimal to no clinically meaningful pain relief compared to intra-articular placebo (saline) injections.
  • Poses significant financial cost and carries a risk of acute post-injection inflammatory flares ("pseudosepsis"—a severe sterile inflammatory reaction with synovial WBC counts >50,000/mcL mimicking septic arthritis).
• Opioid Analgesics: STRONGLY RECOMMENDED AGAINST:
  • Routine use of systemic opioids (tramadol, codeine, oxycodone, fentanyl) is strongly discouraged. Opioids do not improve physical function, carry catastrophic risks of addiction, fatal overdose, sedation, cognitive decline, falls, hip fractures, and opioid-induced hyperalgesia (OIH).

4. Indications for Total Joint Arthroplasty (TJA)

Referral to an orthopedic surgeon for Total Knee Arthroplasty (TKA) or Total Hip Arthroplasty (THA) is indicated when patients fulfill both clinical and radiographic criteria:

1. Severe, persistent, disabling joint pain that significantly impairs activities of daily living (bathing, dressing, ambulating, climbing stairs), causes sleep deprivation, or destroys quality of life;
2. Failure of comprehensive non-surgical management (adequate trials of exercise/PT, weight reduction, assistive devices, and optimized pharmacotherapies);
3. Objective radiographic evidence of advanced joint destruction (Kellgren-Lawrence Grade 3 or 4 joint space collapse, severe sclerosis, bone-on-bone contact).